Education can improve adherence to VTE prophylaxis

Print Friendly, PDF & Email


Elliott Haut (left) and team
Photo courtesy of
Johns Hopkins Medicine
Education can improve adherence to venous thromboembolism (VTE) prophylaxis among hospitalized patients, according to researchers. They assessed data from more than 19,000 hospital stays and found that “real-time” educational interventions directed toward patients and nurses significantly reduced nonadministration of prescribed VTE prophylaxis. However,... [Read Article]
Print Friendly, PDF & Email

Score can predict thrombosis in ITP

Print Friendly, PDF & Email


Thrombus
Image by Andre E.X. Brown
New research suggests a scoring system can predict the risk of thrombosis in patients with immune thrombocytopenia (ITP) who are taking anticoagulants. Researchers tested their Thrombosis and Thrombocytopenia (TH2) risk assessment score in a small group of ITP patients on anticoagulants, and the score identified all seven patients... [Read Article]
Print Friendly, PDF & Email

‘Encouraging’ phase 2 results in rel/ref AML

Print Friendly, PDF & Email


Naval Daver, MD
Photo courtesy of
MD Anderson Cancer Center
The combination of azacitidine and nivolumab produced “encouraging” results in a phase 2 trial of patients with relapsed or refractory acute myeloid leukemia (AML), according to researchers. The overall response rate was 33%, and the median overall survival (OS) was 6.3 months. However, the... [Read Article]
Print Friendly, PDF & Email

FDA approves elotuzumab combo for rel/ref MM

Print Friendly, PDF & Email


Elotuzumab (Empliciti)
Photo courtesy of
Bristol-Myers Squibb
The U.S. Food and Drug Administration (FDA) has approved elotuzumab (Empliciti®) in combination with pomalidomide and dexamethasone. The combination is now approved for use in adults with multiple myeloma (MM) who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor. Elotuzumab is also... [Read Article]
Print Friendly, PDF & Email

Denosumab fights osteoporosis in TDT patients

Print Friendly, PDF & Email


Vials of drug
Photo by Bill Branson
Denosumab can be effective against osteoporosis caused by transfusion-dependent thalassemia (TDT), according to research published in Blood Advances. Researchers found that patients who received twice-yearly injections of denosumab experienced a significant increase in bone density and reduction in bone pain. “Not only is denosumab associated with improved... [Read Article]
Print Friendly, PDF & Email

Novel risk factors for febrile neutropenia in NHL, other cancers

Print Friendly, PDF & Email


Cancer patient receiving chemotherapy
Photo by Rhoda Baer
A retrospective study has revealed new potential risk factors for chemotherapy-induced febrile neutropenia (FN) in patients with solid tumors and non-Hodgkin lymphoma (NHL). Researchers found the timing and duration of corticosteroid use were both associated with FN. The team also observed “marginal” associations between FN... [Read Article]
Print Friendly, PDF & Email

Understanding the role of HSCT in PTCL

Print Friendly, PDF & Email


Ali Bazarbachi, MD, PhD
Hematopoietic stem cell transplant (HSCT) can be hit-or-miss in patients with peripheral T-cell lymphomas (PTCLs), according to a speaker at Leukemia and Lymphoma: Europe and the USA, Linking Knowledge and Practice. Ali Bazarbachi, MD, PhD, of the American University of Beirut in Lebanon, noted that the success of HSCT varies... [Read Article]
Print Friendly, PDF & Email

FDA issues draft guidance on MRD

Print Friendly, PDF & Email


Researcher in the lab
Photo by Darren Baker
The U.S. Food and Drug Administration (FDA) has issued a draft guidance document on the use of minimal residual disease (MRD) assessment in trials of patients with hematologic malignancies. The FDA said it developed this guidance to assist sponsors who are planning to use MRD as... [Read Article]
Print Friendly, PDF & Email

Questions surround MRD assessment in MM

Print Friendly, PDF & Email


Toni Valković, MD, PhD
Clinical trials are needed to answer the many questions related to minimal residual disease (MRD) assessment in multiple myeloma (MM), according to a speaker at Leukemia and Lymphoma: Europe and the USA, Linking Knowledge and Practice. MM patients are increasingly assessed for MRD, which is a strong prognostic factor and... [Read Article]
Print Friendly, PDF & Email

The challenges of diagnosing CMML

Print Friendly, PDF & Email


Micrograph showing CMML
Image by Simon Caulton
Diagnosing chronic myelomonocytic leukemia (CMML) remains a challenge in 2018, according to a presentation at Leukemia and Lymphoma: Europe and the USA, Linking Knowledge and Practice. Even with updated World Health Organization (WHO) criteria, karyotyping, and genetic analyses, it can be difficult to distinguish CMML from other conditions,... [Read Article]
Print Friendly, PDF & Email

Optimizing use of TKIs in CML

Print Friendly, PDF & Email


Hagop Kantarjian, MD
Long-term efficacy and toxicity should inform decisions about tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML), according to the keynote presenter at Leukemia and Lymphoma: Europe and the USA, Linking Knowledge and Practice. Studies have indicated that long-term survival rates are similar whether CML patients receive frontline treatment with imatinib... [Read Article]
Print Friendly, PDF & Email

CDK8 inhibitor can fight AML, though it’s unclear how

Print Friendly, PDF & Email


Eliza Majewska, PhD
The CDK8 inhibitor SEL120 has demonstrated preclinical activity against acute myeloid leukemia (AML), but the agent’s mechanism of action is still unclear. Researchers found that several AML cell lines were “highly sensitive” to SEL120, and the inhibitor was active in primary patient samples. SEL120 also reduced tumor growth in mouse models... [Read Article]
Print Friendly, PDF & Email

GPS appears to predict survival in myelofibrosis

Print Friendly, PDF & Email


Marko Lucijanić, MD, PhD
The Glasgow Prognostic Score (GPS) may predict survival in patients with myelofibrosis (MF), according to research presented at Leukemia and Lymphoma: Europe and the USA, Linking Knowledge and Practice. In a retrospective study, MF patients who were considered intermediate-risk according to the GPS had roughly twice the risk of death... [Read Article]
Print Friendly, PDF & Email

Variant not associated with CLL, AIHA, or ITP in certain patients

Print Friendly, PDF & Email


DNA helix
Image by Spencer Phillips
New research suggests there is no association between the PTPN22 R620W polymorphism and chronic lymphocytic leukemia (CLL) or autoimmune hematologic disorders in patients from the Republic of Macedonia. Past studies have shown an association between the PTPN22 R620W variant and both CLL and autoimmune diseases in patients from... [Read Article]
Print Friendly, PDF & Email